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Background: Hyperlipidemia plays a crucial role in the development and progression of coronary artery disease
(CAD). Recent studies have identified that microRNAs (miRNAs) are important regulators of lipid metabolism, but
little is known about the circulating levels of lipometabolism-related miRNAs and their relationship with the
presence of CAD in patients with hyperlipidemia.
Methods: In the present study, we enrolled a total of 255 hyperlipidemia patients with or without CAD and
100 controls with normal blood lipids. The plasma levels of four known lipometabolism-related miRNAs,
miR-122, miR-370, miR-33a, and miR-33b were quantified by real-time quantitative PCR. Blood levels of total
cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), and high density lipoprotein
cholesterol were determined. Furthermore, the severity of CAD was assessed with the Gensini score system
based on the degree of luminal narrowing and its geographic importance.
Results: Our results revealed for the first time that plasma levels of miR-122 and miR-370 were significantly
increased in hyperlipidemia patients compared with controls, and the levels of miR-122 and miR-370 were
positively correlated with TC, TG, and LDL-C levels in both hyperlipidemia patients and controls. Multiple
logistic regression analysis demonstrated that the increased levels of miR-122 and miR-370 were associated
with CAD presence, even after adjustment for other cardiovascular risk factors. Furthermore, miR-122 and
miR-370 levels were positively correlated with the severity of CAD quantified by the Gensini score. However,
both miR-33a and miR-33b were undetectable in plasma.
Conclusions: Our results suggest that increased plasma levels of miR-122 and miR-370 might be associated
with the presence as well as the severity of CAD in hyperlipidemia patients.
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Atherosclerosis, the major cause of CAD, is character-
ized by accumulation of lipid in the arterial wall result-
ing in narrowing of the vessel lumen [1]. Disorders of
lipid homeostasis have been confirmed to play an im-
portant role in the development and progression of
CAD, and hyperlipidemia has thus been identified as a
major risk factor for CAD [2].
MicroRNAs (miRNAs) are a class of endogenous, non-
coding, single-stranded short RNAs, that negatively
regulate gene expression at the post-transcriptional level
by binding to the 3′untranslated regions of target
mRNAs [3]. Recently, accumulating data from in-vivo
and in-vitro studies have indicated that a variety of
miRNAs, particularly miR-122, miR-370, and miR-33a/b,
play crucial roles in lipid metabolism [4]. Several key
genes involved in fatty acid synthesis and oxidation were
found to be regulated by miR-122, and silencing of
miR-122 resulted in decreased plasma levels of both
total cholesterol (TC) and triglyceride (TG) [5-8]. An-
other miRNA, miR-370, was found to have similar
effects on lipid metabolism as miR-122. In addition,
miR-370 could directly down-regulate the expression of
carnitine palmitoyl transferase 1α gene, which controls
fatty acid oxidation [9]. The miR-33 family, containing
two isoforms (miR-33a and miR-33b), was also shown to
target multiple lipid metabolism-associated genes [10-
14]. Inhibition of miR-33 elevated plasma high density
lipoprotein cholesterol (HDL-C) levels in both normal
and high-fat-diet-fed mice [10-12].
To date, miRNAs in plasma and serum have been con-
sidered as promising novel biomarkers for diagnosis and
prognosis of cardiovascular diseases, especially CAD
[15,16]. However, the circulating levels of lipometabo-
lism-related miRNAs and their relationship with the
presence of CAD in patients with hyperlipidemia remain
to be determined. In the present study, we aimed to
identify the plasma levels of four most prominent
lipometabolism-related miRNAs, miR-122, miR-370,
miR-33a, and miR-33b in patients with hyperlipid-
emia, as well as to determine the relationship be-
tween the miRNAs levels and the presence of CAD.
Materials and Methods
Study subjects
A total of 355 patients who underwent coronary angiog-
raphy for the diagnosis and interventional treatment of
CAD were recruited from inpatients admitted to the
First Affiliated Hospital of Nanjing Medical University.
Hyperlipidemia was defined as TC level of ≥5.72 mmol/L
and/or TG level of ≥1.70 mmol/L, or if the patient was
being treated with lipid-lowering medication [17]. Diag-
nosis of CAD was confirmed by coronary angiography
performed with the Judkins technique using aquantitative coronary angiographic system [18]. CAD
was defined as angiographic evidence of at least one seg-
ment of a main coronary with more than 50 % luminal
narrowing. CAD patients were divided into single-,
double-, and triple-vessel disease subgroups according to
the number of significantly stenosed vessels with refer-
ence to the Coronary Artery Surgery Study classification.
The severity of CAD was assessed with the Gensini score
system based on the degree of luminal narrowing and its
geographic importance [19]. Two cardiologists who were
unaware of the patients included in this study assessed
the angiograms. Patients with histories of significant con-
comitant diseases including hepatic failure, renal failure,
hepatitis, cardiomyopathy, congenital heart disease,
bleeding disorders, previous thoracic irradiation therapy,
and malignant diseases were excluded. Subjects without
clinical evidence of hyperlipidemia and CAD were ran-
domly recruited as control subjects. Hypertension and
diabetes were defined as described in our previous stud-
ies [20]. In brief, hypertension was defined as resting sys-
tolic blood pressure ≥140 mmHg and/or diastolic blood
pressure ≥90 mmHg or in the presence of active antihy-
pertensive treatment. Diabetes was defined as fasting
blood glucose ≥7.0 mmol/L or a diagnosis of diabetes
needing diet or anti-diabetic therapy. Individuals who
formerly or currently smoked ≥10 cigarettes per day for
at least 2 years were defined as smokers. This study was
approved by the First Affiliated Hospital Ethics Commit-
tee of Nanjing Medical University, and informed consent
was obtained from each participant.Laboratory measurements
Fasting blood sample was collected from each subject
and anticoagulated with ethylenediamine tetraacetic acid
(EDTA) dipotassium salt in the early morning. Sample
was separated immediately by centrifugation at 3000 g
for 15 min at 4°C to retrieve plasma. The plasma was
then stored at −80°C until assayed. The levels of plasma
TC, TG, HDL-C, low density lipoprotein cholesterol
(LDL-C), and fasting glucose were detected by an auto-
mated chemical analyzer (Olympus Automated Chemis-
try Analyzer AU5400, Japan).RNA extraction and reverse transcription (RT)
Total RNA was isolated from 400 μL of plasma using
the mirVanaTM PARISTM Kit (Ambion, Austin, TX)
according to the manufacturer’s instructions with modi-
fication. For normalization of sample-to-sample vari-
ation, 25 fmol of synthetic C.elegans miRNA cel-miR-39
(Qiagen, Germany) was added to each sample after
addition of 2× Denaturing Solution (Ambion, Austin,
TX) [21]. RNA was dissolved in 100μL of RNase-free
water, and then stored at −80°C until analysis.
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ManW MiRNA Reverse Kit (Applied Biosystems, Fos-
ter, CA) in 15μL RT reaction containing 5μL of RNA
extract, 0.15μL of 100 mM dNTPs (with dTTP), 1μL
of multiscribe reverse transcriptase (50U/μL), 1.5μL of
10× RT buffer, 0.19μL of RNase inhibitor (20U/μL),
4.16μL of RNase-free water, and 3μL of 5× miRNA-
specific stem-loop RT primer (Applied Biosystems,
Foster, CA). For synthesis of cDNA, the RT reaction
was incubated at 16°C for 30 min, at 42°C for
30 min, at 85°C for 5 min, and then held at 4°C. The
cDNA product was stored at −20°C until analysis.Real-time quantification PCR to detect plasma miRNA
levels
For Real-time quantitative PCR (qRT-PCR), 1.33μL of
the cDNA product was used as template in 20μL reac-
tion containing 1μL of TaqMan miRNA Assay, 7.67μL of
RNase-free water, and 10μL of TaqManW 2× Universal
PCR Master Mix, No AmpEraseW UNG (Applied Biosys-
tems, Foster, CA). qRT-PCR was performed with
7900HT real-time PCR system(Applied Biosystems, Fos-
ter, CA) at 95°C for 10 min, followed by 40 cycles of 95°
C for 15 s and 60°C for 1 min. Triplicate measurements
were obtained for each sample on a 384-well plate. Data
were analyzed with SDS Relative Quantification Software
version 2.2.2 (Applied Biosystems, Foster, CA), with the






Age (years) 63.0 ± 10.7 65.2 ± 10.7
Male, n (%) 35 (70.0 %) 162 (63.5 %)
BMI (kg/m2) 23.7 ± 2.3 24.3 ± 2.8
Smoking, n (%) 22 (44.0 %) 116 (45.5 %)
Hypertension, n (%) 28 (56 %) 159 (62.4 %)
Diabetes, n (%) 9 (18 %) 58 (22.7 %)
Statin therapy, n (%) - 110 (43.1 %)
TC (mmol/L) 4.01 ± 0.73 4.56 ± 0.99
TG (mmol/L) 1.09 ± 0.32 1.90 ± 0.90
LDL-C (mmol/L) 2.48 ± 0.60 2.81 ± 0.70
HDL-C (mmol/L) 1.13 ± 0.18 1.08 ± 0.22
Fasting glucose (mmol/L) 4.95 ± 0.93 5.08 ± 1.41
Number of disease vessels
Single-vessel, n (%) - -
Double-vessel, n (%) - -
Triple-vessel, n (%) - -
CAD= coronary artery disease; BMI = body mass index; TC = total cholesterol; TG = tr
lipoprotein cholesterol.for Ct determination. The relative expression level of
each individual miRNA after normalization to cel-miR-
39 was calculated using the 2-55Ct method.Statistical analysis
Normality of distribution was assessed using the Kolmo-
gorov-Smirnov test. Comparison between 2 groups was
performed with Student’s t tests or Mann–Whitney U tests.
For comparison of more than 2 groups, one-way ANOVA
or Kruskal–Wallis test was used as appropriate. Pearson χ2
test was used to compare qualitative variables represented
as frequencies. The correlations between plasma levels of
miRNAs and other variables were calculated using Spear-
man correlation coefficient. Univariate analysis and multi-
variate logistic regression analysis were taken to determine
the variables that independently contributed to the pres-
ence of CAD. Odds ratio (OR) and 95 % confidence inter-
val (CI) were calculated. All tests were two-sided and
P< 0.05 was considered statistically significant. Statistical
analyses were performed using PASW 18.0 (IBM SPSS,
Inc., Chicago, USA).Results
Characteristics of study subjects
The clinical characteristics of the sample population are
summarized in Table 1. Compared with the controls,
patients with hyperlipidemia had higher levels of TC,










0.162 65.2 ± 10.2 65.3 ± 11.0 0.850
0.382 57 (57.0 %) 105 (67.7 %) 0.082
0.125 23.8 ± 2.6 24.6 ± 2.8 0.024
0.847 34 (34.0 %) 82 (52.9 %) 0.003
0.399 60 (60.0 %) 99 (63.9 %) 0.533
0.459 22 (22.0 %) 36 (23.2 %) 0.820
- 43 (43.0 %) 67 (43.2 %) 0.972
<0.001 4.34 ± 0.91 4.70 ± 1.01 0.013
<0.001 1.78 ± 0.94 1.97 ± 0.87 0.025
0.012 2.68 ± 0.69 2.89 ± 0.69 0.035
0.035 1.11 ± 0.21 1.05 ± 0.22 0.020
0.477 5.08 ± 1.45 5.07 ± 1.39 0.878
- - 52 (33.6 %) -
- - 40 (25.8 %) -
- - 63 (40.6 %) -
iglyceride; LDL-C = low density lipoprotein cholesterol; HDL-C = high density
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(BMI), smoking, hypertension, diabetes, or fasting glu-
cose between two groups. In the hyperlipidemia group,
when compared with CAD patients, non-CAD patients
had a higher prevalence of smoking and higher levels of
BMI, TC, TG, LDL-C, but lower HDL-C. No significant
difference was found in age, gender, hypertension, dia-
betes, fasting glucose, or statin therapy between the two
statuses. By coronary angiography, 52 (33.6 %) CAD
cases had single-vessel disease, 40 (25.8 %) had double-
vessel disease and 63 (40.6 %) had triple-vessel disease.
Plasma levels of miR-122 and miR-370 are increased in
patients with hyperlipidemia
Plasma levels of miR-122 and miR-370 were higher in
patients with hyperlipidemia than in controls (median:
66.5 vs. 33.9, P= 0.008 for miR-122, 52.5 vs. 15.9,
P= 0.001 for miR-370, Figure 1A and 1B). Notably, statin
therapy affected plasma levels of miR-122 and miR-370.
Subgroup analysis revealed significantly lower plasma
levels of miR-122 and miR-370 in statin-treated patients
than in statin-free counterparts (median: 45.2 vs. 79.1,
P=0.012 for miR-122, 40.0 vs. 70.9, P =0.002 for miR-370,Figure 1 Plasma levels of miR-122 and miR-370 in hyperlipidemia pat
miR-122 (A) and miR-370 (B) are increased in hyperlipidemia patients com
(D) are decreased in statin-treated patients compared with statin-free patieFigure 1C and 1D). However, plasma levels of miR-33a
and miR-33b were below the detection limit in both the
hyperlipidemia and control groups.
The correlations of plasma levels of miR-122 and miR-370
with blood lipid profiles
We further analyzed the correlations of plasma levels of
miR-122 and miR-370 with blood lipid profiles. As shown
in Table 2, the plasma levels of miR-122 and miR-370 were
positively correlated with TC, TG, and LDL-C levels in
both control subjects and statin-free patients with hyper-
lipidemia, whereas no significant correlation was observed
between miRNA levels and HDL-C levels. Still, a positive
correlation between plasma levels of miR-122 and miR-370
was also found. However, there was no significant associ-
ation between miRNA levels and blood lipid profiles in sta-
tin-treated patients with hyperlipidemia.
Increased plasma levels of miR-122 and miR-370 are
associated with the presence of CAD in patients with
hyperlipidemia
In the hyperlipidemia group, CAD patients had higher
plasma levels of miR-122 and miR-370 than non-CAD
patients (median: 78.5 vs. 59.5, P= 0.023 for miR-122,ients and controls with normal blood lipids. Plasma levels of
pared with control subjects. Plasma levels of miR-122 (C) and miR-370
nts.
Table 2 Spearman correlations of plasma levels of
miR-122 and miR-370 with blood lipid profiles
TC TG LDL-C HDL-C miR-122 miR-370
Controls
(n = 100)
miR-122 0.351* 0.229* 0.352* -0.033 - 0.448**





miR-122 0.322** 0.363** 0.357** -0.049 - 0.363**
miR-370 0.178* 0.379** 0.211* 0.108 0.363** -
Statin-treated
(n= 110)
miR-122 0.099 0.068 0.055 -0.038 - 0.466**
miR-370 0.083 0.040 0.102 0.024 0.466** -
Correlations are presented as correlation coefficients (R) and significance
(P< 0.05) is indicated as follows: * P< 0.05, ** P< 0.001.
TC = total cholesterol; TG = triglyceride; LDL-C = low density lipoprotein
cholesterol; HDL-C = high density lipoprotein cholesterol.
Table 3 Univariate analysis and multiple logistic
regression analysis for the risk of CAD in patients with
hyperlipidemia
Models OR 95 % CI P value
miR-122
Univariate analysis 1.08 1.01–1.16 0.015
Multiple logistic regression model 1a 1.08 1.01–1.16 0.024
Multiple logistic regression model 2b 1.09 1.01–1.17 0.023
Multiple logistic regression model 3c 1.08 1.01–1.16 0.034
miR–370
Univariate analysis 1.05 1.01–1.10 0.014
Multiple logistic regression model 1a 1.04 1.01–1.10 0.011
Multiple logistic regression model 2b 1.04 1.01–1.09 0.011
Multiple logistic regression model 3c 1.05 1.01–1.12 0.022
a The model included age, gender, BMI, and smoking.
b The model included age, gender, BMI, smoking, hypertension, and diabetes.
c The model included age, gender, BMI, smoking, hypertension, diabetes, TC,
TG, LDL-C, and HDL-C.
OR= odds ratio; CI = confidence interval.
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Univariate and multivariate logistic regression analysis
revealed that plasma levels of miR-122 and miR-370
were significantly associated with the presence of CAD,
even after adjustment for age, gender, BMI, smoking,
hypertension, diabetes, and blood lipid profiles (Table 3).
The correlations of plasma levels of miR-122 and miR-370
with the severity of CAD
CAD patients were subdivided into three subgroups
(single-, double- and triple-vessel disease) according to
the number of affected coronary arteries. As the number
of affected vessels increased, the Gensini score signifi-
cantly increased (median: 10.0 vs. 33.5 vs. 53.0, P
< 0.001, Figure 3A). However, no significant differenceFigure 2 Plasma levels of miR-122 and miR-370 in hyperlipidemia pat
miR-370 (B) are increased in patients with CAD compared with those withoin miR-122 and miR-370 levels was found among the
three subgroups (median: 79.1 vs. 63.1 vs. 80.2, P= 0.784
for miR-122, 101.2 vs. 130.5 vs. 63.5, P = 0.555 for
miR-370). Spearman correlation analysis demonstrated
positive correlations of miR-122 and miR-370 levels
with the severity of CAD, quantified by the Gensini
score (R = 0.265, P = 0.040 for miR-122, R = 0.247,
P = 0.014 for miR-370, Figure 3B and 3C).
Discussion
Although accumulating evidence suggests that miRNAs
are important regulators of lipid metabolism, little is
known about the circulating levels of these lipometabo-
lism-related miRNAs and their relationship with the
presence of CAD in patients with hyperlipidemia. In the
present study, we demonstrated for the first time that
plasma levels of lipometabolism-related miR-122 andients with and without CAD. Plasma levels of miR-122 (A) and
ut CAD. CAD= coronary artery disease.
Figure 3 The correlations of plasma levels of miR-122 and
miR-370 with the severity of CAD.(A) Gensini score increases as
the number of affected vessels increases. Plasma levels of miR-122
(B) and miR-370 (C) are positively correlated with the Gensini score.
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patients compared with controls, and the levels of
miR-122 and miR-370 were positively correlated with
TC, TG, and LDL-C levels in both hyperlipidemia
patients and controls. Furthermore, the increased
levels of miR-122 and miR-370 were associated with
CAD presence, independent of other cardiovascular
risk factors. In addition, miR-122 and miR-370 levels
were positively correlated with the severity of CAD
quantified by the Gensini score. However, both miR-
33a and miR-33b were undetectable in plasma, indi-
cating that miR-33a/b might not present in plasma.
It has been shown that miR-122 and miR-370 are
over-expressed in the livers of hyperlipidemia animals
[7,9,22]. The present study is the first to investigate the
circulating levels of miR-122 and miR-370 in patients
with hyperlipidemia. Indeed, plasma levels of miR-122
and miR-370 were also increased in patients with hyper-
lipidemia, and positively correlated with TC, TG, and
LDL-C levels, suggesting that circulating miR-122 and
miR-370 might be used as novel biomarkers for hyper-
lipidemia. In addition, Iliopoulos et al. [9] reported that
transfection of the human hepatic cell line HepG2 with
miR-370 could up-regulate the expression of miR-122.
In the present study, we also found a positive correlation
between plasma levels of miR-122 and miR-370, indicat-
ing that similar regulation might also exist in circulating
system.
Considering the crucial role of hyperlipidemia in the
onset and development of CAD, dysregulation of lipo-
metabolism-related miRNAs might also be related to the
presence of CAD. Previous studies have found that ex-
pression levels of miR-122 are increased in infarcted
areas as well as in border areas after acute myocardial
infarction (AMI) [23,24]. Hoekstra et al. [25] also
reported that miR-370 levels were higher in peripheral
blood mononuclear cells from patients with unstable an-
gina pectoris as compared to patients with stable angina
pectoris. Our observations of increased plasma levels of
miR-122 and miR-370 in hyperlipidemia patients with
CAD in comparison with those without CAD are con-
sistent with these previous findings and suggest that the
increased levels of miR-122 and miR-370 might be novel
risk factors for CAD.
In contrast to previous findings and our results,
D’Alessandra et al. [24] found that plasma levels of
miR-122 were lower in AMI patients than healthy
controls. Corsten’s study [26] indicated that the
plasma level of miR-122 was elevated in acute heart
failure, while no significant change was observed in
patients with AMI and myocardial diastolic dysfunc-
tion. Similarly, Wang et al. [27] found no significant
difference of plasma miR-122 levels between AMI
patients and healthy subjects. The different
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122 level and CAD may be explained, at least in
part, by the different characters of patients among
different studies. Our study population is a cohort of
patients with hyperlipidemia, whereas other studies
focus on patients with AMI without regard to the
blood lipid levels. Another possibility that may ac-
count for the observed inconsistencies across studies
is that the sample sizes of other studies were smaller
than our study. Nevertheless, further studies includ-
ing larger and different patient cohorts are needed
to fully evaluate the relationship between plasma
miR-122 level and CAD.
The clinical significance of circulating lipometabolism-
related miRNAs in CAD is another aspect of great interest.
To the best of our knowledge, no data has been published
on the association of the circulating miRNAs with the se-
verity of CAD. Our study demonstrated positive correla-
tions of plasma levels of both miR-122 and miR-370 with
the Gensini score, indicating that plasma levels of miR-122
and miR-370 increased as the severity of CAD increased.
Thus, the potential prognostic value of these two lipometa-
bolism-related miRNAs in CAD needs to be further evalu-
ated. At the same time, it has been reported that miRNAs
levels are reduced after statin therapy [28,29]. Our data also
showed that plasma levels of miR-122 and miR-370 were
lower in statin-treated patients than in statin-free subjects.
Therefore, we speculate that statin therapy may also cause
the reduction of circulating lipometabolism-related miR-
NAs. Further experimental studies are needed to explore
the mechanisms by which statin therapy influences the cir-
culating levels of lipometabolism-related miRNAs.
In conclusion, this study shows that plasma levels of
miR-122 and miR-370 are increased in patients with
hyperlipidemia and positively correlated with TC, TG,
and LDL-C levels. Furthermore, the increased levels of
miR-122 and miR-370 were associated with CAD pres-
ence. High miR-122 and miR-370 levels seemed to posi-
tively correlate with the severity of CAD.
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